Melanoma is the most aggressive and life-threatening form of skin cancer, causing more than 70% of skin cancer deaths. The metastatic stage represents the last step of melanoma progression but constitutes the major challenge to the development of effective treatments. Current available therapies are not definitive for advanced stage melanoma and often present limitations such as side effects and drug resistance. Therefore, to improve the overall clinical outcome there is still a need to develop more specific therapies for metastatic melanoma. Nanomaterials are promising tools for drug delivery, as they can be designed to overcome biological barriers, to selectively target cancer cells, and to effectively delivery therapeutic agents to the tumour.